You are here: Welcome » COVID-19 Vaccines » Lipid Nanoparticles in COVID-19 Vaccines

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
covid-19_vaccines:lipid_nanoparticle [2022/03/03 02:13]
liam [Intellectual Property and Patents] 		covid-19_vaccines:lipid_nanoparticle [2022/11/24 19:45] (current)
liam [Intellectual Property and Patents]
Line 13: Line 13:
 ===== Intellectual Property and Patents ===== ===== Intellectual Property and Patents =====
  
-The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial.+The ownership and licensure of the LNP technology underlying the [[:mRNA]] [[:COVID-19 vaccines]] is controversial. See the below graphic from //Patent network analysis of mRNA-based vaccine candidates for COVID-19//:((Gaviria, M., & Kilic, B. (2021). //A network analysis of COVID-19 mRNA vaccine patents.// Nature Biotechnology, 39(5), 546–548. https://doi.org/10.1038/s41587-021-00912-9)) 
 + 
 +{{:covid-19_vaccines:41587_2021_912_fig1_html_copy.jpg?600 |}}
  
 ==== Patents ==== ==== Patents ====
Line 19: Line 21:
 The following patents are involved in the development of the LNP technology in question: The following patents are involved in the development of the LNP technology in question:
  
-  * 2201121 - BILAYER STABILIZING COMPONENTS AND THEIR USE IN FORMING PROGRAMMABLE FUSOGENIC LIPOSOMES((Madden, T. D., Cullis, P. R., & Holland, J. W. (1994). //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes// (Canadian Intellectual Property Office Patent No. 2201121). https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2201121/summary.html?type=number_search&tabs1Index=tabs1_1))+  * 2201121 - //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes//((Madden, T. D., Cullis, P. R., & Holland, J. W. (1994). //Bilayer stabilizing components and their use in forming programmable fusogenic liposomes// (Canadian Intellectual Property Office Patent No. 2201121). https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2201121/summary.html?type=number_search&tabs1Index=tabs1_1))
 ==== Legal Challenges ==== ==== Legal Challenges ====
  
Line 25: Line 27:
  
 The suit alleges that Moderna had licensed Arbutus' LNP technology for its products, but not specifically for their [[:moderna_mrna-1273|mRNA-1273]] [[:COVID-19 vaccines|COVID-19 vaccine product]]. While the companies are seeking financial compensation, they insist they do not intend to halt or otherwise impede the distribution of the product. Moderna denied the allegations, claiming they had created their own proprietary lipid nanoparticle delivery technology for use in their [[:mRNA]] platform. The suit alleges that Moderna had licensed Arbutus' LNP technology for its products, but not specifically for their [[:moderna_mrna-1273|mRNA-1273]] [[:COVID-19 vaccines|COVID-19 vaccine product]]. While the companies are seeking financial compensation, they insist they do not intend to halt or otherwise impede the distribution of the product. Moderna denied the allegations, claiming they had created their own proprietary lipid nanoparticle delivery technology for use in their [[:mRNA]] platform.
 +
 +
Back to top